Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT01221168
Recruiting Observational

Epidemiologic and Genetic Study on Familial Prostate Cancer

NCT01221168 · tracked via the Priya Life Science France tracker
Sponsor
Centre de Recherche sur les Pathologies Prostatiques
Phase
Observational
Started
1996-10
Last updated
2025-05-23

Condition(s) studied

Prostate Cancer

Study summary

The aims of the study are:

* to identify genetic and molecular factors (rare mutations, polymorphisms) involved in the natural history of prostate cancers and their response to treatment,
* to evaluate and deduce their medical applications for screening and therapeutic management of these tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * patient with a histological confirmed prostate cancer * member of a hereditary prostate cancer family * healthy control men without prostate cancer Exclusion Criteria: * Absence of signed informed consent * refusal to participate in the study

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Department of Urology, CHU Angers Angers France Recruiting
Department of Urology, Hopital de la Cavale Blanche Brest France Recruiting
Department of Urology, CHU Dijon Dijon France Recruiting
Department of Urology, Hopital Pitié-Salpetriere Paris France Recruiting
Department of Urology, Hopital Tenon Paris France Completed

Other trials for the same condition

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Active, not recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse Recruiting
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients Active, not recruiting
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18) Active, not recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01221168 on ClinicalTrials.gov ↗ ← All trials in France